Nurix Therapeutics Inc’s recently made public that its Chief Legal Officer Ring Christine unloaded Company’s shares for reported $67314.0 on Dec 18 ’25. In the deal valued at $17.90 per share,3,760 shares were sold. As a result of this transaction, Ring Christine now holds 50,897 shares worth roughly $0.96 million.
Then, CHRISTINE RING bought 7,520 shares, generating $136,939 in total proceeds.
Before that, Ring Christine sold 37,600 shares. Nurix Therapeutics Inc shares valued at $641,697 were divested by the Chief Legal Officer at a price of $17.07 per share. As a result of the transaction, Ring Christine now holds 50,897 shares, worth roughly $0.96 million.
Morgan Stanley upgraded its Nurix Therapeutics Inc [NRIX] rating to an Overweight from a an Equal-weight in a research note published recently. Mizuho began covering NRIX with “an Outperform” recommendation on October 21, 2025. Leerink Partners started covering the stock on March 17, 2025. It rated NRIX as “a Market perform”.
Price Performance Review of NRIX
On Tuesday, Nurix Therapeutics Inc [NASDAQ:NRIX] saw its stock jump 2.99% to $18.93. Over the last five days, the stock has gained 8.61%. Nurix Therapeutics Inc shares have risen nearly 3.78% since the year began. Nevertheless, the stocks have fallen -0.21% over the past one year.
How much short interest is there in Nurix Therapeutics Inc?
A steep rise in short interest was recorded in Nurix Therapeutics Inc stocks on 2025-12-31, growing by 0.16 million shares to a total of 14.64 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 14.49 million shares. There was a rise of 1.07%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 10, 2024 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
